Preclinical research reveals mifamurtide boosts chemotherapy effectiveness in chondrosarcoma, indicating new treatment strategies may improve outcomes.
Key Points
Combining mifamurtide with doxorubicin shows enhanced antitumoral efficacy in chondrosarcoma models.
Mifamurtide is found to increase chemosensitivity in specific chondrosarcoma spheroid cultures.
Targeting tumor-associated macrophages reveals potential for improving treatment success against chondrosarcoma.
Results support further exploration of immunomodulator and chemotherapy combinations in cancer therapy.